Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

KADCYLA is the third personalized medicine Roche has developed for the treatment of HER2-positive breast cancer, after HERCEPTIN and PERJETA™. Roche licenses technology for KADCYLA under an ...

This means that Roche’s one-year Herceptin treatment will remain the standard therapy for patients suffering from early-stage HER2-positive breast cancer. The study did not have any new safety ...

Roche’s breast cancer arsenal, including Kadcyla and Herceptin, could be facing strong competition, with biosimilar copies of Herceptin now on the market and December’s U.S. approval of Daiichi Sankyo ...

The European Medicines Agency began a review in 2012 after an inspection identified some safety data relating to these drugs that had not previously been provided by Roche. The therapies covered by ...

Roche's biologics focus and innovative pipeline are key to the firm's ability to maintain its wide economic moat and continue to achieve growth as current blockbusters mature. Three fourths of Roche's ...

Roche announced that the European Commission has approved Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who ...

Survival outcomes for people with HER2-positive breast cancer, once seen as an aggressive type of the disease, have been transformed through the development of targeted therapies, including Roche ...

MISSISSAUGA, ON, Sept. 4, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved PERJETA (pertuzumab) in combination with HERCEPTIN ® (trastuzumab ...

Roche`s application is being reviewed under the US FDA`s Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application ...

Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion ...

Roche noted that the new drug regimen is the first to show an increase in PFS compared to Herceptin plus chemotherapy. Analysts have predicted that sales of Perjeta could reach $600m to $1bn within ...